{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T15:27:18Z","timestamp":1790954838150,"version":"4.1.0"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180888"],"award-info":[{"award-number":["U10CA180888"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10CA180819"],"award-info":[{"award-number":["U10CA180819"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","award":["5U01CA180888-08"],"award-info":[{"award-number":["5U01CA180888-08"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb Company","doi-asserted-by":"publisher","award":["5UG1CA233198-05"],"award-info":[{"award-number":["5UG1CA233198-05"]}],"id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Associations between immune-related adverse events from checkpoint inhibitor therapy and outcomes have been previously evaluated, with most prior research finding a positive association between toxicity and survival. This prior research has generally reported on more common tumor types. We use a unique data resource of a federally funded basket trial (NCT02834013) for patients with rare cancers (n\u2009=\u2009684) to evaluate associations between immune-related adverse events and overall survival and progression-free survival (PFS).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients were treated with nivolumab and ipilimumab; the trial was opened at more than 1000 sites. Landmark Cox regression models were used to assess first cycle immune-related adverse event associations with PFS and overall survival.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found that grade 1-2 treatment-related immune-related adverse events in the first cycle of therapy were associated with longer overall survival (multivariable hazard ratio [HR] = 0.61, 95% confidence interval [CI] = 0.49 to 0.75; P\u2009&amp;lt;\u2009.001) compared with no treatment-related immune-related adverse event, while grade 3-4 immune-related adverse events were associated with shorter overall survival (HR\u2009=\u20091.41, 95% CI\u2009=\u20091.04 to 1.90; P\u2009=\u2009.025). Similar but weaker associations were observed with PFS and grade 1-2 treatment-related immune-related adverse events (HR\u2009=\u20090.83, 95% CI\u2009=\u20090.67 to 1.01; P\u2009=\u2009.067) and grade 3-4 (HR\u2009=\u20091.35, 95% CI\u2009=\u20091.02 to 1.78; P\u2009=\u2009.037) compared with no treatment-related immune-related adverse events. Grade 1-2 dermatologic toxicity was associated with improved overall survival compared with other grade 1-2 toxicities (HR\u2009=\u20090.67, 95% CI\u2009=\u20090.52 to 0.85; P\u2009=\u2009.002). There was no statistically significant overall survival difference between patients with grade 1-2 fatigue, gastrointestinal, metabolic, hepatic, endocrine, and thyroid toxicities vs other grade 1-2 toxicities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In this large cohort of patients with rare tumors receiving checkpoint inhibitor therapy, grade of immune-related adverse event in the first cycle was predictive for survival.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jnci\/djae297","type":"journal-article","created":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T19:36:08Z","timestamp":1732131368000},"page":"692-700","source":"Crossref","is-referenced-by-count":10,"title":["First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors"],"prefix":"10.1093","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8176-6371","authenticated-orcid":false,"given":"Megan","family":"Othus","sequence":"first","affiliation":[{"name":"SWOG Cancer Research Network Statistical Center , Seattle, WA 98109,","place":["United States"]},{"name":"Biostatistics Program, Public Health Division, Fred Hutchinson Cancer Center , Seattle, WA 98109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8387-4840","authenticated-orcid":false,"given":"Sandip P","family":"Patel","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, University of California at San Diego Moores Cancer Center , La Jolla, CA 92037,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1557-7235","authenticated-orcid":false,"given":"Young Kwang","family":"Chae","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Northwestern University , Chicago, IL 60611,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8836-0374","authenticated-orcid":false,"given":"Eliana","family":"Dietrich","sequence":"additional","affiliation":[{"name":"Biostatistics Program, Public Health Division, Fred Hutchinson Cancer Center , Seattle, WA 98109,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-9804","authenticated-orcid":false,"given":"Howard","family":"Streicher","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-9719","authenticated-orcid":false,"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health , Bethesda, MD 20892,","place":["United States"]},{"name":"Department of Medicine, Dana-Farber\/Harvard Cancer Center , Boston, MA 02215,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4110-1214","authenticated-orcid":false,"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[{"name":"Department of Medicine, Medical College of Wisconsin , Milwaukee, WI 53226,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,20]]},"reference":[{"key":"2025040623581528600_djae297-B1","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/bjd.20074","article-title":"Effect of dermatological consultation on survival in patients with checkpoint inhibitor-associated cutaneous toxicity","volume":"185","author":"Thompson","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025040623581528600_djae297-B2","doi-asserted-by":"crossref","first-page":"2826","DOI":"10.3390\/cancers13112826","article-title":"Toxicity, response and survival in older patients with metastatic melanoma treated with checkpoint inhibitors","volume":"13","author":"de Glas","year":"2021","journal-title":"Cancers"},{"key":"2025040623581528600_djae297-B3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.jgo.2021.02.002","article-title":"Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer","volume":"12","author":"Johns","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"2025040623581528600_djae297-B4","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jamaoncol.2022.2081","article-title":"Association between toxic effects and survival in patients with cancer and autoimmune disease treated with checkpoint inhibitor immunotherapy","volume":"8","author":"Han","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025040623581528600_djae297-B5","doi-asserted-by":"crossref","first-page":"7457","DOI":"10.1002\/cam4.4239","article-title":"Preexisting immune-mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors","volume":"10","author":"Gulati","year":"2021","journal-title":"Cancer Med"},{"key":"2025040623581528600_djae297-B6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000300","article-title":"Immune-related adverse events and survival in solid tumors treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"43","author":"Petrelli","year":"2020","journal-title":"J Immunother"},{"key":"2025040623581528600_djae297-B7","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/oncolo\/oyad154","article-title":"Immune-related adverse events and clinical outcomes in advanced urothelial cancer patients treated with immune checkpoint inhibitors","volume":"28","author":"Sanda","year":"2023","journal-title":"Oncologist"},{"key":"2025040623581528600_djae297-B8","doi-asserted-by":"crossref","first-page":"e006786","DOI":"10.1136\/jitc-2023-006786","article-title":"Dysthyroidism during immune checkpoint inhibitors is associated with improved overall survival in adult cancers: data mining of 1385 electronic patient records","volume":"11","author":"Beaufils","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025040623581528600_djae297-B9","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","article-title":"Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma","volume":"145","author":"Indini","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025040623581528600_djae297-B10","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025040623581528600_djae297-B11","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1200\/JCO.19.00318","article-title":"Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody","volume":"37","author":"Maher","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025040623581528600_djae297-B12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","article-title":"Association of anti\u2013programmed cell death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma","volume":"5","author":"Quach","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025040623581528600_djae297-B13","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non\u2013small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025040623581528600_djae297-B14","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1007\/s00262-020-02802-6","article-title":"Thyroid dysfunction induced by immune checkpoint inhibitors is associated with a better progression-free survival and overall survival in non-small cell lung cancer: an original cohort study","volume":"70","author":"Thuillier","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"2025040623581528600_djae297-B15","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.annonc.2021.05.357","article-title":"The positive effect of immune checkpoint inhibitor-induced thyroiditis on overall survival accounting for immortal time bias: A retrospective cohort study of 6596 patients","volume":"32","author":"Street","year":"2021","journal-title":"Ann Oncol"},{"key":"2025040623581528600_djae297-B16","doi-asserted-by":"crossref","first-page":"102134","DOI":"10.1016\/j.ctrv.2020.102134","article-title":"Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors\u2013a systematic review and meta-analysis","volume":"92","author":"Hussaini","year":"2021","journal-title":"Cancer Treatment Rev"},{"key":"2025040623581528600_djae297-B17","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002535","article-title":"Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis","volume":"9","author":"Tarhini","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025040623581528600_djae297-B18","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaad.2022.12.048","article-title":"Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort study","volume":"88","author":"Zhang","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025040623581528600_djae297-B19","doi-asserted-by":"crossref","first-page":"107790","DOI":"10.1016\/j.lungcan.2024.107790","article-title":"Endocrine immune-related adverse event is a prognostic biomarker independent of lead-time bias","volume":"192","author":"Ishidoya","year":"2024","journal-title":"Lung Cancer"},{"key":"2025040623581528600_djae297-B20","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.1983.1.11.710","article-title":"Analysis of survival by tumor response","volume":"1","author":"Anderson","year":"1983","journal-title":"J Clin Oncol"},{"key":"2025040623581528600_djae297-B21","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/cncr.33591","article-title":"A phase II basket trial of Dual Anti\u2013CTLA\u20134 and Anti\u2013PD\u20131 Blockade in Rare Tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort","volume":"127","author":"Patel","year":"2021","journal-title":"Cancer"},{"key":"2025040623581528600_djae297-B22","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-19-3356","article-title":"A Phase II basket trial of dual anti\u2013CTLA-4 and anti\u2013PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors","volume":"26","author":"Patel","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2025040623581528600_djae297-B23","volume-title":"Dual anti-CTLA-4 and anti-PD-1 Blockade In Metaplastic Carcinoma of the Breast: Dart (SWOG S1609, Cohort 36)","author":"Adams","year":"2020"},{"key":"2025040623581528600_djae297-B24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025040623581528600_djae297-B25","article-title":"A phase II basket trial of Dual Anti\u2013CTLA-4 and Anti\u2013PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025040623581528600_djae297-B26","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"2025040623581528600_djae297-B27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"2025040623581528600_djae297-B28","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s12967-020-02612-5","article-title":"Revisiting the association between skin toxicity and better response in advanced cancer patients treated with immune checkpoint inhibitors","volume":"18","author":"Gulati","year":"2020","journal-title":"J Trans Med"},{"key":"2025040623581528600_djae297-B29","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1182\/asheducation-2015.1.225","article-title":"Graft-versus-host disease versus graft-versus-leukemia","volume":"2015","author":"Negrin","year":"2015","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"2025040623581528600_djae297-B30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1182\/blood.V100.2.406","article-title":"Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse","volume":"100","author":"Lee","year":"2002","journal-title":"Blood"},{"key":"2025040623581528600_djae297-B31","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1158\/1078-0432.CCR-20-4856","article-title":"Differential effect of graft-versus-host disease on survival in acute leukemia according to donor type","volume":"27","author":"Konuma","year":"2021","journal-title":"Clinical Cancer Research"},{"key":"2025040623581528600_djae297-B32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1093\/jnci\/djt072","article-title":"Impact of EGFR inhibitor in non\u2013small cell lung cancer on progression-free and overall survival: a meta-analysis","volume":"105","author":"Lee","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2025040623581528600_djae297-B33","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.7150\/jca.32205","article-title":"Relationship between progression-free survival and overall survival in randomized clinical trials of targeted and biologic agents in oncology","volume":"10","author":"Hess","year":"2019","journal-title":"J Cancer"},{"key":"2025040623581528600_djae297-B34","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1200\/JCO.23.00225","article-title":"Irreconcilable differences: the divorce between response rates, progression-free survival, and overall survival","volume":"41","author":"Merino","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025040623581528600_djae297-B35","first-page":"266","article-title":"Importance of low-and moderate-grade adverse events in patients\u2019 treatment experience and treatment discontinuation: an analysis of the E1912 trial","volume":"23","author":"O\u2019Connell","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025040623581528600_djae297-B36","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1200\/JCO.24.00191","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025040623581528600_djae297-B37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1080\/14712598.2020.1813276","article-title":"The potential role of tumor-derived exosomes in diagnosis, prognosis, and response to therapy in cancer","volume":"21","author":"Czystowska-Kuzmicz","year":"2021","journal-title":"Expert Opinion Biol Ther"},{"key":"2025040623581528600_djae297-B38","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","journal-title":"J Immunother Cancer"}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djae297\/60768340\/djae297.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/4\/692\/60768340\/djae297.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/117\/4\/692\/60768340\/djae297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T23:58:59Z","timestamp":1743983939000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/117\/4\/692\/7905479"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,20]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,20]]},"published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djae297","relation":{},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,11,20]]}}}